HIGHLIGHTS
- who: Dafne Jacome Sanz and colleagues from the Laboratory of Immunoregulation, Faculty of Medicine and Health Technology, Tampere University, Ltd, Tampere University Hospital, Tampere, Finland have published the article: Evaluating Targeted Therapies in Ovarian Cancer Metabolism: Novel Role for PCSK9 and Second Generation mTOR Inhibitors, in the Journal: (JOURNAL)
- what: The authors aimed to investigate the therapeutic value of targeting lipid in OC. The authors investigated the role of PCSK9, the proprotein convertase subtilisin/kexin type-9 regulating cholesterol and lipid metabolism, in OC cell survival and its intracellular signaling, in cell lines (n=8 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.